DIETARY SUPPLEMENT FORMULATED BASED ON ALL-TRANS FORM OF MENAQUINONE-7

Abstract

The present invention is directed to a dietary supplement comprising a trans form of Menaquinone-7 (MK-7). In some embodiments, the dietary supplement may further comprise at least one chondroprotective agent. In some embodiments, the dietary supplement comprises metal ions selected from the group consisting of zinc ions, copper ions, manganese ions, magnesium ions, iron ions, chromium ions, calcium ions, and combinations thereof.

Claims

1. A dietary supplement comprising a trans form of Menaquinone-7 (MK-7).

2. The dietary supplement of claim 1, further comprising at least one chondroprotective agent.

3. The dietary supplement of claim 1, further including at least one ingredient selected from the group consisting of vitamins, minerals, amino acids, antioxidants, and anti-inflammatory agents.

4. The dietary supplement of claim 1, further comprising metal ions selected from the group consisting of zinc ions, copper ions, manganese ions, magnesium ions, iron ions, chromium ions, calcium ions, and combinations thereof.

5. The dietary supplement of claim 4, wherein the metal ions are selected from the group consisting of manganese ions, zinc ions, and copper ions, wherein the dietary supplement further comprises the ligand 2-hydroxy-4-methylthiobutanoic acid.

6. The dietary supplement of claim 1, further comprising vitamin C, biotin, vitamin D3, selenium, calcium, phosphate, and 2-hydroxy-4-methylthiobutanoic acid.

7. The dietary supplement of claim 1, further comprising dried molasses, flax oil, yeast culture, and alfalfa meal.

8. The dietary supplement of claim 1, further comprising magnesium, vitamin C, selenium, calcium, and vitamin D3

9. A medicament for the therapeutic or prophylactic treatment of joint conditions, comprising the trans-form of Menaquinone-7 (MK-7).

10. A method for promoting at least one of pain relief, growth, repair, or maintenance of bone or joint tissue in a mammalian subject, the method comprising administering to the mammalian subject the medicament of claim 9.

11. The method of claim 10, wherein the medicament comprises the all-trans form of MK-7 and at least one chondroprotective agent.

12. The method of claim 10, wherein the medicament further comprises at least one ingredient selected from the group consisting of vitamins, minerals, metal ions, amino acids, antioxidants, and anti-inflammatory agents.

13. The method of claim 12, wherein the metal ions are selected from the group consisting of zinc ions, copper ions, manganese ions, magnesium ions, iron ions, chromium ions, calcium ions, and combinations thereof.

14. The method of claim 12, wherein the metal ions are selected from the group consisting of manganese ions, zinc ions, and copper ions, and the medicament additionally comprises the ligand 2-hydroxy-4-methylthiobutanoic acid

15. The method of claim 10, wherein the mammalian subject is selected from the group consisting of animals and humans.

16. The method of claim 10, wherein the mammalian subject has a joint-related indication.

17. The method of claim 16, wherein the joint-related indication is selected from the group consisting of osteoarthritis, rheumatoid arthritis, psoriatic arthritis, joint effusion, joint inflammation or pain, synovitis, lameness, post-operative arthroscopic surgery, deterioration of proper joint function, the inhibition of metabolic activity of chondrocytes, and the inhibition of the production of hyaluronic acid.

Description

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

[0065] The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:

[0066] FIG. 1 shows the chemical structure of the all-trans form of Menaquinone-7.

[0067] FIG. 2 shows a graph of MGP expression.

REFERENCES

[0068] Altinel L, Sahin O, Kose K C, Bas O, Ozen O A, Saritas Z K, et al. Healing of osteochondral defects in canine knee with avocado/soybean unsaponifiables: a morphometric comparative analysis. Eklem Hastalik Cerrahisi. 2011; 22(1):48-53. [0069] Andrew M T. arthritis in animals with dietary supplements. U.S. Pat. No. 6,524,609B1. [0070] Boileau C, Martel-Pelletier J, Caron J, Msika P, Guillou G B, Baudouin C, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis Res Ther. 2009; 11(2):R41. [0071] Christensen R, Bartels E M, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008; 16(4):399-408. [0072] Cindy W. Nutritional supplements. US20070065456A1. [0073] Dinubile N A. A potential role for avocado- and soybeanbased nutritional supplements in the management of osteoarthritis: a review. Phys Sportsmed. 2010; 38(2):71-81. [0074] Gabay O, Gosset M, Levy A, Salvat C, Sanchez C, Pigenet A, et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by avocado-soybean unsaponifiables (ASU). Osteoarthritis Cartilage. 2008; 16(3):373-84. [0075] Jeremy D, Moore T R, Hampton R H. Dietary supplements for promotion of growth. repair, and maintenance of bone and joints, U.S. Pat. No. 8,968,791B2, [0076] John M S, Hill C M, Use of eggshell membrane formulations to alleviate joint pain. WO2011062953A1. [0077] Kevin S. Cartilage enhancing food supplements and methods of preparing the same, WO2004004686A2. [0078] Lippiello L, Nardo J V, Harlan R, Chiou T. Metabolic effects of avocado/soy unsaponifiables on articular chondrocytes. Evid Based Complement Alternat Med. 2008; 5(2):191-7. [0079] Marni M H. Joint preserving nutritional vitamin, mineral and herbal pet supplement. U.S. Pat. No. 8,703,174B2. [0080] Nathaniel D, Albert D M, Laberge J, Campisi M, Demaria A, Vasserot C, Kim O, Jeon J, Elisseeff J, Kirkland T, Tchkonia, Yi Z, Treatment of joint pain. U.S. Ser. No. 10/130,628B2. [0081] Patricia M P, Rukmini C, Reddy S, Cherukuri V, Mohammed M, Methods for treating joint inflammation, pain, and loss of mobility. U.S. Pat. No. 6,902,739B2. [0082] Paul T Q, Cees V. Vitamin K2 containing food product. CA2347387C. [0083] Shearer M J, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemostasis. 2008, 100(10):530-547. [0084] Suketsune I, Takehito K. Medicine and functional food. JP2006169205A. [0085] Szterk A, Bus K, Zmysłowski A, Ofiara K. Analysis of Menaquinone-7 Content and Impurities in Oil and Non-Oil Dietary Supplements. Molecules. 2018, 23(5):1056.